Publications
Discover peer-reviewed publications by therapeutic area.
The information on this page pertains to select publication resources. It is not intended to serve as a comprehensive list of all publications resources.
If you would like to discover more educational content, please use the “Search” feature.
Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.
The provision of this content is not intended to recommend or suggest use of its products in any manner inconsistent with local regulatory approval. For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.
Primary Hyperoxaluria Type 1 (PH1)
Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial
Pediatric Nephrology
Acute Hepatic Porphyria (AHP)
Hyperhomocysteinemia in acute hepatic porphyria (AHP) and implications for treatment with givosiran
Expert Review of Gastroenterology & Hepatology
Acute Hepatic Porphyria (AHP)
Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study
Orphanet Journal of Rare Diseases
Transthyretin Amyloidosis (ATTR)
Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial
Amyloid
Primary Hyperoxaluria Type 1 (PH1)
Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial
American Journal of Kidney Diseases
Acute Hepatic Porphyria (AHP)
Patient Perspective on Acute Hepatic Porphyria with Sporadic Attacks: A Chronic Disease with Substantial Health-Related Quality of Life Impacts
Advances in Therapy
Transthyretin Amyloidosis (ATTR)
Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation
American Journal of Transplantation
Primary Hyperoxaluria Type 1 (PH1)
Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1
Kidney International Reports
Primary Hyperoxaluria Type 1 (PH1)
Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young children
Genetics in Medicine
Primary Hyperoxaluria Type 1 (PH1)
Primary Hyperoxaluria Type 1 Disease Manifestations and Healthcare Utilization: A Multi-Country, Online, Chart Review Study
Frontiers in Medicine
